These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 31253744)

  • 1. Preclinical Evaluation of
    Banerjee SR; Minn I; Kumar V; Josefsson A; Lisok A; Brummet M; Chen J; Kiess AP; Baidoo K; Brayton C; Mease RC; Brechbiel M; Sgouros G; Hobbs RF; Pomper MG
    J Nucl Med; 2020 Jan; 61(1):80-88. PubMed ID: 31253744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Evaluation of a New Series of Albumin-Binding
    Boinapally S; Alati S; Jiang Z; Yan Y; Lisok A; Singh R; Lofland G; Minn I; Hobbs RF; Pomper MG; Banerjee SR
    Molecules; 2023 Aug; 28(16):. PubMed ID: 37630410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.
    Kiess AP; Minn I; Vaidyanathan G; Hobbs RF; Josefsson A; Shen C; Brummet M; Chen Y; Choi J; Koumarianou E; Baidoo K; Brechbiel MW; Mease RC; Sgouros G; Zalutsky MR; Pomper MG
    J Nucl Med; 2016 Oct; 57(10):1569-1575. PubMed ID: 27230930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Evaluation of
    Banerjee SR; Lisok A; Minn I; Josefsson A; Kumar V; Brummet M; Boinapally S; Brayton C; Mease RC; Sgouros G; Hobbs RF; Pomper MG
    J Nucl Med; 2021 Jul; 62(7):980-988. PubMed ID: 33246975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single Chelator-Minibody Theranostic Agents for
    Ho KV; Tatum DS; Watkinson L; Carmack T; Jia F; Mascioni A; Maitz CA; Magda D; Anderson CJ
    J Nucl Med; 2024 Sep; 65(9):1435-1442. PubMed ID: 39142831
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Banerjee SR; Kumar V; Lisok A; Chen J; Minn I; Brummet M; Boinapally S; Cole M; Ngen E; Wharram B; Brayton C; Hobbs RF; Pomper MG
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2545-2557. PubMed ID: 31399803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
    Benešová M; Umbricht CA; Schibli R; Müller C
    Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Improved
    Mease RC; Kang CM; Kumar V; Banerjee SR; Minn I; Brummet M; Gabrielson KL; Feng Y; Park A; Kiess AP; Sgouros G; Vaidyanathan G; Zalutsky MR; Pomper MG
    J Nucl Med; 2022 Feb; 63(2):259-267. PubMed ID: 34088772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hetero-bivalent agents targeting FAP and PSMA.
    Boinapally S; Lisok A; Lofland G; Minn I; Yan Y; Jiang Z; Shin MJ; Merino VF; Zheng L; Brayton C; Pomper MG; Banerjee SR
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4369-4381. PubMed ID: 35965291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinoma.
    Singh R; Thotakura AK; Alati S; Lisok A; Jiang Z; Merino VF; Minn I; Yadav S; Markowski MC; Ged Y; Pavlovich CP; Singla N; Solnes LB; Gorin MA; Pomper MG; Rowe SP; Banerjee SR
    Front Oncol; 2024; 14():1432286. PubMed ID: 39324008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
    Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
    J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer.
    Shen CJ; Minn I; Hobbs RF; Chen Y; Josefsson A; Brummet M; Banerjee SR; Brayton CF; Mease RC; Pomper MG; Kiess AP
    Theranostics; 2020; 10(7):2888-2896. PubMed ID: 32194842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
    Deberle LM; Benešová M; Umbricht CA; Borgna F; Büchler M; Zhernosekov K; Schibli R; Müller C
    Theranostics; 2020; 10(4):1678-1693. PubMed ID: 32042329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates.
    Banerjee SR; Foss CA; Pullambhatla M; Wang Y; Srinivasan S; Hobbs RF; Baidoo KE; Brechbiel MW; Nimmagadda S; Mease RC; Sgouros G; Pomper MG
    J Nucl Med; 2015 Apr; 56(4):628-34. PubMed ID: 25722448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of
    Banerjee SR; Kumar V; Lisok A; Plyku D; Nováková Z; Brummet M; Wharram B; Barinka C; Hobbs R; Pomper MG
    J Nucl Med; 2019 Mar; 60(3):400-406. PubMed ID: 30237212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403.
    Ling X; Latoche JD; Choy CJ; Kurland BF; Laymon CM; Wu Y; Salamacha N; Shen D; Geruntho JJ; Rigatti LH; Windish HP; Langton-Webster B; Berkman CE; Anderson CJ
    Mol Imaging Biol; 2020 Apr; 22(2):274-284. PubMed ID: 31321650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen.
    Kiess AP; Minn I; Chen Y; Hobbs R; Sgouros G; Mease RC; Pullambhatla M; Shen CJ; Foss CA; Pomper MG
    J Nucl Med; 2015 Sep; 56(9):1401-1407. PubMed ID: 26182968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
    Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
    J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.